Wedbush initiated coverage of Sarepta (SRPT) with an Outperform rating and $32 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Grants CEO Equity Awards After Eight Years
- Needham starts Solid Biosciences at Buy on opening in DMD market
- Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline
- Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges
- Sarepta gets FDA approval to test Elevidys regimen in non-ambulant patients